MedTrace Logo

BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer

NCT00708214 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2013-12-30

Study results available
· View outcomes & findings →

Summary

Progression-free rate after 16 weeks of BIBW 2992 administration in association with letrozole

Conditions

  • Breast Neoplasms

Interventions

DRUG

BIBW 2992

BIBW 2992 at high and medium dosages

DRUG

BIBW 2992

BIBW 2992 at high and medium dosages

DRUG

Letrozole

Letrozole at standard dosage

DRUG

Letrozole

Letrozole at standard dosage

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2010-02-28

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00708214 on ClinicalTrials.gov